Author

J. Nie

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

PURPOSE To evaluate the safety and efficacy of the novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate, trastuzumab botidotin, for the treatment of HER2-positive unresectable/metastatic breast cancer (BC). METHODS In this phase III, open-label, multicenter trial (ClinicalTrials.gov...

Jian Zhang, Q. Ouyang, Qing-Yuan Zhang et al. · Journal of Clinical Oncology · 0 citations

Open access Sep 2026

Targeting mitochondrial EGFR by CTAB in triple-negative breast cancer

EGFR is an oncogenic factor highly expressed in multiple tumor types. While previous research has primarily focused on plasma membrane-localized EGFR, the role of its mitochondrial localization (mitoEGFR) in breast cancer remains poorly understood. This study reveals that EGFR is enriched in mitochondria in triple-ne...

Yuan-Zhen Li, Si-Yuan Yang, Xu Yang et al. · Cell Death & Disease · 0 citations

Aug 2026

ACOD1 enhances the ferroptosis resistance of tumor-associated macrophages through the KEAP1/NRF2 axis and promotes triple-negative breast cancer progression.

ACOD1 is highly expressed in TNBC TAMs and is driven by TME signals, independent of the classical M2 polarization pathway, and promotes ITA binding to KEAP1, which inhibits the KEAP1-NRF2 interaction and thus activates NRF2-mediated antioxidant and ferroptosis resistance responses in TAMs, promoting TNBC progression.

Jie Yang, Xiyin Li, Xin Qu et al. · Pathology, Research and Prac... · 1 citation